Clinical trials: Myeloid
Leukemia, Myeloid, Acute
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.
- Trial name
- NCT02348489
- Testing
- SGI-110 (guadecitabine), Treatment Choice
- Where
- 135 sites in United States, Australia and 22 more
- Volunteers
- 815 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid…
- Trial name
- NCT06328179
- Testing
- Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Huai'an First People's Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis
- Trial name
- NCT00255346
- Testing
- Dasatinib (BMS-354825)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
AML
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
This is a single-arm, open-label clinical trial evaluating the safety and preliminary efficacy of a novel induction regimen combining Venetoclax, Azacitidine, and Liposomal Mitoxantrone (VAM) in patients with newly diagnosed…
- Trial name
- NCT07490288
- Testing
- Venetoclax, Azacitidine, Liposomal Mitoxantrone
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia, Myeloid, Philadelphia-Positive
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
The purpose of this study is to determine if PEG-Intron is better tolerated and more efficacious than standard interferons (Roferon, Intron) in patients with Philadelphia-positive Chronic Myelogenous Leukemia.
- Trial name
- NCT00037882
- Testing
- PEG-Intron
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients with stage III or stage…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002980
- Testing
- decitabine
- Where
- 4 sites in United States
- Sponsor
- California Cancer Consortium
Acute Myeloid Leukemia
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
This is a phase 1 study to test the safety of escalating doses of elesclomol sodium given to patients with advanced myeloid leukemia.
- Trial name
- NCT01280786
- Testing
- Elesclomol Sodium
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Synta Pharmaceuticals Corp.
Hematologic Malignancy, Acute Myeloid Leukemia
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
Phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CLL1-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
- Trial name
- NCT03795779
- Testing
- CLL1-CD33 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Acute Myeloid Leukemia
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
This study is an open-label, single arm phase II study which will examine the efficacy and toxicity of the combination therapy of GO, mitoxantrone and etoposide in patients who did not respond to first line induction therapy.
- Trial name
- NCT03839446
- Testing
- mitoxantrone + etoposide + gemtuzumab ozogamicin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Robert Redner, MD
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for degradation through caspase-directed cleavage.
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT01398462
- Testing
- CWP232291
- Where
- 5 sites in United States, South Korea
- Volunteers
- 69 people
- Sponsor
- JW Pharmaceutical
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Evaluation of 3 Different Doses of IV Busulfan
Albeit the safety of the stem cell transplantation procedure has been greatly improved, further refining the intensity of the conditioning is an important issue to explore, especially in patients with poor prognosis, the goal…
- Trial name
- AAA (NCT01985061)
- Testing
- BX2, BX3, BX4-Suspended
- Where
- France
- Volunteers
- 177 people
- Sponsor
- Institut Paoli-Calmettes
Leukemia
Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00083070
- Testing
- temozolomide
- Where
- 16 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
IDH1 Mutation, Relapsed / Refractory AML
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
This is a prospective, single-arm phase 2 pilot study to assess the response rate of IDH1 mutated relapsed/refractory acute myeloid leukemia (AML) patients who receive olutasidenib after progressing on venetoclax based regimens.
- Trial name
- NCT07471841
- Testing
- Olutasidenib, Azacitidine (AZA)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Timothy Pardee
Acute Myeloid Leukemia
Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML
To determine the feasibility of fludarabine and cytarabine as continuous infusion plus granulocyte-colony stimulating factor priming for elderly patients with resistant acute myeloid leukemia other than acute promyelocytic…
- Trial name
- NCT00529880
- Testing
- Fludarabine , cytarabine
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Cooperative Study Group A for Hematology
Leukemia, Myeloid, Chronic-Phase
Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
This is a multicentre, single-arm study of nilotinib 300 mg BID in newly diagnosed patients with CP-CML. This study is designed to establish the disappearance of Ph+ stem cells (CD34+/lin-) in BM during nilotinib treatment.
- Trial name
- NCT01856283
- Testing
- Nilotinib 300mg BID
- Where
- 17 sites in Italy
- Volunteers
- 87 people
- Sponsor
- Niguarda Hospital
Acute Myeloid Leukemia (AML)
Molecular Diagnostic Platform for AML
This will be a translational study without any therapeutic intervention, for the purpose of analyzing the diagnostic and molecular results / characterization of adult patients with AML, regardless of the treatment they receive.
- Trial name
- NCT04446741
- Where
- 7 sites in Spain
- Volunteers
- 2,000 people
- Sponsor
- PETHEMA Foundation
Neoplasms, Hematologic Neoplasms
Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL/AML, and to evaluate the…
- Conditions
- Neoplasms, Hematologic Neoplasms, Hematologic Diseases
- Trial name
- NCT05907603
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Kai Lin Xu，MD
Sepsis, Trauma Injury
Microbiome Dysfunction in Surgical Intensive Care Unit Survivors
Oral and gastrointestinal microbiome dysfunction has been demonstrated to be a culprit of various systemic dysfunctions in peripheries such as cardiovascular, nervous, endocrine and musculoskeletal systems.
- Trial name
- NCT05357170
- Testing
- Human feces collection
- Where
- United States
- Volunteers
- 468 people, healthy volunteers welcome
- Sponsor
- University of Florida
Leukemia
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
To determine if AEG35156 can enhance the combined complete remission (CR) and CR with incomplete platelet recovery (CRp) rate of high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine…
- Trial name
- NCT01018069
- Testing
- AEG35156
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 60 people
- Sponsor
- Aegera Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.